Disease Domain | Count |
---|---|
Neoplasms | 4 |
Endocrinology and Metabolic Disease | 2 |
Nervous System Diseases | 2 |
Infectious Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Vaccine | 1 |
AAV based gene therapy | 1 |
Prophylactic vaccine | 1 |
Target- |
Mechanism Microbiome modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Microbiome modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date08 Nov 2023 |
Sponsor / Collaborator |
Start Date01 Aug 2023 |
Sponsor / Collaborator |
Start Date14 Jul 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
AB-1224 | Autistic Disorder More | Phase 2 |
AB-4166 | Parkinson Disease More | Clinical |
ML241 ( VCP ) | Neoplasms More | Preclinical |
Mosaic-8b ( SARS-CoV-2 S protein ) | COVID-19 More | Preclinical |
TRAMMAE-4 | Neoplasms More | Preclinical |